BE875739A - COMPOSITIONS INCLUDING PLATINUM - Google Patents
COMPOSITIONS INCLUDING PLATINUMInfo
- Publication number
- BE875739A BE875739A BE0/194741A BE194741A BE875739A BE 875739 A BE875739 A BE 875739A BE 0/194741 A BE0/194741 A BE 0/194741A BE 194741 A BE194741 A BE 194741A BE 875739 A BE875739 A BE 875739A
- Authority
- BE
- Belgium
- Prior art keywords
- emi
- composition according
- substituted
- groups
- equal
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 14
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title claims description 12
- 229910052697 platinum Inorganic materials 0.000 title claims description 4
- 150000007942 carboxylates Chemical class 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 125000002577 pseudohalo group Chemical group 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical class OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical class O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000047 product Substances 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- -1 halide ions Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Paul Cedric Hydes/ David Malcolm Watkins <EMI ID=1.1>
tion de platine, et des compositions pharmaceutiques comprenant ces composés et l'utilisation des compositions pharmaceutiques pour le traitement de tumeurs et néoplasmes malignes.
En accord avec un premier objet de la présente invention, l'invention concerne une composition comprenant un composé de coordination cis de platine ayant la structure suivante:
<EMI ID=2.1>
dans lesquelles X et Y,qui peuvent être les mêmes ou différents, sont choisis dans le groupe comprenant halogène, pseudohalogène, sulphate, phosphate, nitrate, carboxylate, carboxylate substitué et eau et A et B , qui peuvent être les mêmes égaux ou différents, sont des amino -acides coordinés au Pt à travers leur atomes
<EMI ID=3.1>
n devrait, de préférence être tnnombre entier entre 1 et 9 et les groupes R peuvent être égaux ou différents et choisis parmi hydrogène, alky Je substitué ou non substitué à chaîne droite ou
<EMI ID=4.1>
Deux groupes R ensemble peuvent aussi représenter un atome d'oxygène ou de souffre lié par une double liaison.
Si X et Y représentent tous les deux un carboxylate ils peuvent représenter ensemble un dicarboxylate , comme par exemple oxalate,ou des groupes de la formule :
<EMI ID=5.1>
<EMI ID=6.1> <EMI ID=7.1>
dicarboxylate) et ceux-ci peuvent être substitués ou non substitués.
Les amino- acides de la présente invention ont la formule générale suivante:
<EMI ID=8.1>
dans laquelle x est 1,2 ou 3 et les groupes R sont égaux ou différents et choisis parmi hydrogène, alky3e substitué ou non
<EMI ID=9.1>
ou les esters ou sels de celui-ci, deux groupes R peuvent aussi représenter ensemble un atome d'oxygène ou de souffre.
<EMI ID=10.1>
carboxylate substitué de sorte que m est un nombre entier entre
<EMI ID=11.1>
parmi l'hydrogène, alkyJe substitué ou non substitué à chaîne droi-
<EMI ID=12.1>
<EMI ID=13.1>
un atome d'oxygène ou de souffre lié par une double liaison.
<EMI ID=14.1>
L'expression "pseudohalogène" utilisée dans la présente invention a le sens donné à la page 560 de "Advanced Inorganic Chemistry" de Cotton and Wilkinson, Interscience Publishers,
1966 . Selon cette litérature les "pseudohalogènes" sont
des molécules constituées de deux ou plusieurs atomes électronégatifs , qui , à l'état libre , ressemblent à des halogènes , ces pseudohalogènes fournissent des anions, qui, en ce qui concerne leur comportement, ressemblent à des ions halogénures.
Jes exemples de pseudohalogènes appropriés sont le cyanure,
le cyanate, le thiocyanate et l'acide.
Il a été trouvé que les composés de la présente invention peuvent être utilisés avec succès contre le cancer.
ou des tumeurs et néoplasmes malignes. Normalement les composés de l'invention sont utilisés ensemble avec un support ou/diluants phamaceutiques acceptables. En accord avec un second objet de la
<EMI ID=15.1>
prenant un composé tel que décrit ci-dessus en mélange avec
un diluant ou un support approprié du point de vue pharmaceutique.
<EMI ID=16.1>
tumeur ou un néoplasme maligne.
D'autres objets et avantages de l'invention seront mieux compris à la lecture de la description qui va suivre de plusieurs exemples de réalisation.
1. cis-(dichloro(glycine) platine (II))
<EMI ID=17.1>
charbon actif et filtrés à travers un filtre fritté préchauffé dans 53,52 g de glycine et 40 g de KOH (6 moles équivalents) dans 100 ml d'eau chaude. La solution obtenue fut transvasée
<EMI ID=18.1>
tes jusqu'à la décoloration de la solution. La solution fut alors refroidie à la température de laboratoire. Ensuite, sous agitation vigoureuse , 30 ml d'HCl concentré furent
<EMI ID=19.1>
de porosité 3 . Le produit obtenu fut lavé copieusement avec de l'eau et séché sous vide à 50[deg.]C.
Le solide blanc fut suspendu dans 250 ml d'eau et maintenu pendant 3 heures à 80[deg.]C. La solution fut refroidie et filtrée à travers un filtre fritté de porosité 3 . Le produit fut lavé avec de l'eau et séché sous vide à 60[deg.]C.
Le rendement était de 29,90 g (73%).
<EMI ID=20.1>
60 ml d'HCL concentré. Ensuite le mélange fut agité et chauffé pendant 10 minutes à 50[deg.]C. Le mélange, qui contenait le complexe dichloro jaune, fut refrofli dans de la glace et filtré à travers
un filtre fritte de porosité 3. Le produit fut lavé avec de l'acide chlorhydrique concentré, de l'ëthanole et de l'éther et. séché sous vide à 60[deg.]C.
Le rendement était de 11,7 g (81%).
<EMI ID=21.1>
<EMI ID=22.1>
à 42,34g d'alanine et 26,68 g d'hydroxyde de potassium dans de l'eau chaude(75 ml). La solution obtenue fut chauffée sur une plaque
<EMI ID=23.1>
(approximativement une heure). De l'acide chlorhydrique concentré fut alors ajouté goutte à goutte afin de porter le pH de la solu-
<EMI ID=24.1>
cnauffée sur une plaque chauffante pendant 4 heures jusqu'à ce que
le volume était de 325 ml. La solution fut refrddie et le précipité blanc fut récupéré filtration sur un filtre fritté de porosité 3.
<EMI ID=25.1>
et séché sous vide à 60[deg.]C.
Le rendement était de 8,8 g (20%).
Par concentration de la solution mère à 225 ml et refroidissement de cette solution à la température de laboratoire du cis-Pt(an)2 additionnel put être obtenu.
4,0 g de cis- Pt(an)2 furent chauffés sur une plaque chauffante . avec 10 ml de HC1 concentré pendant une minute à 60[deg.]C.
Le mélange fut alors' refroidi à la température de laboratoire et transféré sur un filtre fritté de porosité 3 avec un volume minimum d'HCl concentré froid. Le produit jaune fut laissé sur le
<EMI ID=26.1>
<EMI ID=27.1>
Bien entendu diverses modifications peuvent être apportées par l'homme de l'art aux dispositifs ou procédés qui viennent d'être décrits uniquement à titre d'exemples non limitatifs sans sortir du cadre de l'invention.
i
<EMI ID=28.1>
<EMI ID=29.1>
caractérisée en ce que ce composé a la formule générale:
<EMI ID=30.1>
dans laquelle X et Y sont égaux ou différents et choisis dans le groupe comprenant halogène, pseudohalogène, sulphate, phosphate, nitrate, carboxylate, carboxylate substitué et eau, A et B sont égaux ou différents et représentent des amino-acides coordinés ou Pt à travers leur atomes d'azote, et X représente des groupes choisis parmi halogène, pseudohalogène ou hydroxy.
Paul Cedric Hydes / David Malcolm Watkins <EMI ID = 1.1>
tion of platinum, and pharmaceutical compositions comprising these compounds and the use of the pharmaceutical compositions for the treatment of malignant tumors and neoplasms.
In accordance with a first object of the present invention, the invention relates to a composition comprising a cis coordination compound of platinum having the following structure:
<EMI ID = 2.1>
wherein X and Y, which may be the same or different, are selected from the group consisting of halogen, pseudohalogen, sulphate, phosphate, nitrate, carboxylate, substituted carboxylate and water and A and B, which may be the same equal or different, are amino acids coordinated to Pt through their atoms
<EMI ID = 3.1>
n should preferably be an integer between 1 and 9 and the R groups may be the same or different and selected from hydrogen, straight chain substituted or unsubstituted alkyl or
<EMI ID = 4.1>
Two R groups together can also represent an oxygen or sulfur atom linked by a double bond.
If X and Y both represent a carboxylate they can together represent a dicarboxylate, such as for example oxalate, or groups of the formula:
<EMI ID = 5.1>
<EMI ID = 6.1> <EMI ID = 7.1>
dicarboxylate) and these can be substituted or unsubstituted.
The amino acids of the present invention have the following general formula:
<EMI ID = 8.1>
in which x is 1, 2 or 3 and the groups R are equal or different and chosen from hydrogen, substituted or unsubstituted alkyl
<EMI ID = 9.1>
or esters or salts thereof, two R groups can also together represent an oxygen or sulfur atom.
<EMI ID = 10.1>
substituted carboxylate so that m is an integer between
<EMI ID = 11.1>
from hydrogen, substituted or unsubstituted straight chain alkyl
<EMI ID = 12.1>
<EMI ID = 13.1>
an oxygen or sulfur atom linked by a double bond.
<EMI ID = 14.1>
The expression "pseudohalogen" used in the present invention has the meaning given on page 560 of "Advanced Inorganic Chemistry" by Cotton and Wilkinson, Interscience Publishers,
1966. According to this literature, "pseudohalogens" are
molecules made up of two or more electronegative atoms, which in the free state resemble halogens, these pseudohalogens provide anions, which in their behavior resemble halide ions.
Examples of suitable pseudohalogens are cyanide,
cyanate, thiocyanate and acid.
It has been found that the compounds of the present invention can be used successfully against cancer.
or malignant tumors and neoplasms. Normally the compounds of the invention are used together with an acceptable pharmaceutical carrier or diluents. In accordance with a second object of the
<EMI ID = 15.1>
taking a compound as described above mixed with
a pharmaceutically suitable diluent or carrier.
<EMI ID = 16.1>
tumor or malignant neoplasm.
Other objects and advantages of the invention will be better understood on reading the following description of several exemplary embodiments.
1. cis- (dichloro (glycine) platinum (II))
<EMI ID = 17.1>
activated carbon and filtered through a sintered filter preheated in 53.52 g of glycine and 40 g of KOH (6 mole equivalents) in 100 ml of hot water. The solution obtained was transferred
<EMI ID = 18.1>
test until the solution becomes discolored. The solution was then cooled to laboratory temperature. Then, with vigorous stirring, 30 ml of concentrated HCl was
<EMI ID = 19.1>
porosity 3. The product obtained was washed copiously with water and dried in vacuo at 50 ° C.
The white solid was suspended in 250 ml of water and held for 3 hours at 80 ° C. The solution was cooled and filtered through a sintered filter of porosity 3. The product was washed with water and dried in vacuo at 60 [deg.] C.
The yield was 29.90 g (73%).
<EMI ID = 20.1>
60 ml of concentrated HCL. Then the mixture was stirred and heated for 10 minutes at 50 [deg.] C. The mixture, which contained the yellow dichloro complex, was refilled in ice and filtered through.
a sintered filter of porosity 3. The product was washed with concentrated hydrochloric acid, ethanol and ether and. vacuum dried at 60 [deg.] C.
The yield was 11.7 g (81%).
<EMI ID = 21.1>
<EMI ID = 22.1>
to 42.34g of alanine and 26.68g of potassium hydroxide in hot water (75ml). The resulting solution was heated on a plate
<EMI ID = 23.1>
(approximately one hour). Concentrated hydrochloric acid was then added dropwise to raise the pH of the solution.
<EMI ID = 24.1>
puffed on a hot plate for 4 hours until
the volume was 325 ml. The solution was refrddie and the white precipitate was collected filtration through a sintered filter of porosity 3.
<EMI ID = 25.1>
and vacuum dried at 60 [deg.] C.
The yield was 8.8 g (20%).
By concentrating the stock solution to 225 ml and cooling this solution to laboratory temperature, additional cis-Pt (an) 2 could be obtained.
4.0 g of cis-Pt (an) 2 was heated on a hot plate. with 10 ml of concentrated HCl for one minute at 60 [deg.] C.
The mixture was then cooled to laboratory temperature and transferred to a sintered filter of porosity 3 with a minimum volume of cold concentrated HCl. The yellow product was left on the
<EMI ID = 26.1>
<EMI ID = 27.1>
Of course, various modifications can be made by those skilled in the art to the devices or methods which have just been described by way of non-limiting examples without departing from the scope of the invention.
i
<EMI ID = 28.1>
<EMI ID = 29.1>
characterized in that this compound has the general formula:
<EMI ID = 30.1>
wherein X and Y are equal or different and selected from the group consisting of halogen, pseudohalogen, sulphate, phosphate, nitrate, carboxylate, substituted carboxylate and water, A and B are equal or different and represent coordinated amino acids or Pt through their nitrogen atoms, and X represents groups selected from halogen, pseudohalogen or hydroxy.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1565978 | 1978-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
BE875739A true BE875739A (en) | 1979-08-16 |
Family
ID=10063134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE0/194741A BE875739A (en) | 1978-04-20 | 1979-04-20 | COMPOSITIONS INCLUDING PLATINUM |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPS54154718A (en) |
BE (1) | BE875739A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3128144A1 (en) * | 1981-07-16 | 1983-02-03 | Basf Ag, 6700 Ludwigshafen | Cis-dichloroplatinum(II)-amino acid complexes |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2751068A1 (en) * | 2009-01-31 | 2010-08-05 | Igf Oncology, Llc | Anti-cancer protein-platinum conjugates |
-
1979
- 1979-04-20 JP JP4892179A patent/JPS54154718A/en active Pending
- 1979-04-20 BE BE0/194741A patent/BE875739A/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3128144A1 (en) * | 1981-07-16 | 1983-02-03 | Basf Ag, 6700 Ludwigshafen | Cis-dichloroplatinum(II)-amino acid complexes |
Also Published As
Publication number | Publication date |
---|---|
JPS54154718A (en) | 1979-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2481696A1 (en) | ORGANOPLATIN COMPLEXES WITH ANTI-TUMOR ACTIONS | |
JPS58177934A (en) | Benzoquinone derivative | |
FR2463776A1 (en) | COMPOSITIONS COMPRISING CIS AND CIS-TRANS COORDINATION COMPOUNDS OF PLATINUM | |
CH659075A5 (en) | PROCESS FOR THE PREPARATION OF A PLATINUM OLIGOMER (II), THESE OLIGOMERS AND THEIR USE. | |
US4704464A (en) | Tumor retarding (1-benzyl-ethylenediamine)-platin (II)-complexes | |
FR2534907A1 (en) | DIAMINE-PLATIN COMPLEXES, PROCESS FOR THEIR PREPARATION, PROCESS FOR THE PREPARATION OF A MEDICINAL COMPOSITION USING SUCH PLATINUM DIAMINE COMPLEX FOR THE TREATMENT OF CANCER AND THE COMPOSITION THUS FORMED | |
US4228090A (en) | Compositions containing platinum | |
FR2655339A2 (en) | COMPOUNDS AND COMPLEXES USEFULLY IN MEDICAL IMAGING. | |
BE875739A (en) | COMPOSITIONS INCLUDING PLATINUM | |
LU84464A1 (en) | TRIARYLBORANEISOCYANO-METAL COMPOUNDS | |
EP0007834B1 (en) | Process for the preparation of optically active alpha-amino acids and their derivatives | |
FR2505330A1 (en) | NOVEL CARCINOSTATIC SUBSTANCE BASED ON N- (4- (3-AMINOPROPYL) AMINOBUTYL) -2 - ((S) -7-GUANIDINO-3-HYDROXYHAPTANAMIDO) -2-HYDROXYETHANAMIDE DERIVATIVE AND PROCESS FOR PREPARING THE SAME | |
CH479552A (en) | Process for the preparation of ketimines | |
BE875740A (en) | COMPOSITIONS INCLUDING PLATINUM | |
JP3125101B2 (en) | Resolution method of optical isomer hydantoin | |
JP2006520360A (en) | Protein-binding derivatives of platinum complexes having cyclobutane-1,1-dicarboxylate ligands | |
BE875738A (en) | COMPOUNDS INCLUDING PLATINUM | |
US3651134A (en) | 5-arylalkoxy-1-hydroxy-2-naphthoic acids | |
US4094904A (en) | Process of racemizing an optically active phenyl glycine amide with or without a substituted phenyl group | |
JPS601316B2 (en) | organic germanium compounds | |
US4370493A (en) | Synthesis of alpha-amino acids | |
US4371705A (en) | Synthesis of alpha-amino acids | |
US3790598A (en) | Process for preparing alpha-amino acids | |
US3109024A (en) | Method of preparing thyroxine and its analogs | |
US4375555A (en) | Synthesis of alpha-amino acids |